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Background: Marine microorganisms are an important source of new drug leads. However, the discovery and
sustainable production of these compounds are often hampered due to the unavailable expression of cryptic
biosynthetic gene clusters or limited titer. Ribosome engineering and response surface methodology (RSM) integrated
strategy was developed in this study to activate cryptic gene cluster in the deepsea-derived Streptomyces somaliensis
SCSIO ZH66, and subsequently isolation, structural analysis, and the yield enhancement of the activated compound,
anticancer drug lead Fredericamycin A (FDM A), were performed.
Results: In order to discover novel natural products from marine Streptomyces strains by genome mining strategy, the
deepsea-derived S. somaliensis SCSIO ZH66 was subject to ribosome engineering to activate the expression of cryptic
gene clusters. A resistant strain ZH66-RIF1 was thereby obtained with 300 μg/mL rifampicin, which accumulated a
brown pigment with cytotoxicity on MS plate while absent in the wild type strain. After screening of fermentation
conditions, the compound with pigment was purified and identified to be FDM A, indicating that the activation of
a cryptic FDM A biosynthetic gene cluster was taken place in strain ZH66-RIF1, and then it was identified to be
ascribed to the mutation of R444H in the β subunit of RNA polymerase. To further improve the yield efficiently,
nine fermentation medium components were examined for their significance on FDM A production by Plackett–
Burman design and Box-Behnken design. The optimum medium composition was achieved by RSM strategy,
under which the titer of FDM A reached 679.5 ± 15.8 mg/L after 7 days of fermentation, representing a 3-fold
increase compared to the original medium. In terms of short fermentation time and low-cost fermentation
medium, strain ZH66-RIF1 would be an ideal alternative source for FDM A production.
Conclusions: Our results would hasten the efforts for further development of FDM A as a drug candidate.
Moreover, this ribosome engineering and RSM integrated methodology is effective, fast and efficient; it would be
applicable to genome mining for novel natural products from other strains.
Keywords: Deepsea-derived Streptomyces, Ribosome engineering, Cryptic Gene cluster, Response Surface
Methodology (RSM), Fredericamycin A (FDM A)* Correspondence: liwenli@ouc.edu.cn
†Equal contributors
1Key Laboratory of Marine Drugs, Ministry of Education of China, School of
Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
Full list of author information is available at the end of the article
© 2015 Zhang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Zhang et al. Microbial Cell Factories  (2015) 14:64 Page 2 of 11Introduction
After years of screening from soil dwelling microorgan-
isms, it is more and more difficult to discover novel com-
pounds through traditional screening strategies, which
increases the drug development costs and drains the pipe-
line of natural product drugs. Marine microorganisms, es-
pecially Streptomyces, have become an important source
of pharmacologically active metabolites [1,2]. Because mar-
ine environmental conditions are extremely different from
the terrestrial environment [3], it is surmised that marine
microorganisms have different characteristics from their
terrestrial counterparts and, therefore, might produce dif-
ferent types of bioactive compounds. Marine Streptomyces
are widely distributed in the oceans and, more importantly,
novel compounds with biological activities have been iso-
lated from them at a high frequency, indicating that marine
Streptomyces are an important source for drug discovery.
However, the discovery and sustainable production of bio-
active compounds are often hampered due to the unavail-
able expression of cryptic biosynthetic gene clusters or
limited incubation and testing conditions [4].
Over the past decade, actinomycete genome sequen-
cing has revealed that many secondary metabolites
biosynthetic gene clusters are “silent” under ordinary
laboratory conditions [5,6], which greatly precluded
discovery of novel bioactive compounds. Ribosome engin-
eering targeting ribosomal proteins or RNA polymerase
(RNAP) has been proved to be effective for waking up and
upregulation of the expression of cryptic gene clusters
[6-8], leading to discovery of cyclic peptide Piperidamycin
A [9] and chlorinated alkaloids Inducamides A–C [10]. In
our efforts to discover novel natural products from marine
Streptomyces strains by using genome mining strategy,
deepsea-derived Streptomyces somaliensis SCSIO ZH66
was isolated, identified and subject to ribosome engineer-
ing to activate the cryptic gene clusters in the genome. A
rifampicin-resistant mutant strain accumulating dark
brown pigment was obtained; the pigment was purified
and identified as anticancer drug lead Fredericamycin
(FDM) A.
FDM A, first isolated from terrestrial Streptomyces gri-
seus ATCC49344 in 1981 [11], is an aromatic pentadeca-
ketide featuring two sets of peri-hydroxy tricyclic aromatic
moieties connected through a unique asymmetric carbas-
piro center, representing a new chemotype for anticancer
drug leads [12]. The cytotoxicity of FDM A against tumor
cell lines resulted from inhibition of DNA topoisomerases
I and II as well as the peptidyl-prolyl cis/trans isomerase
Pin1, which is involved in the regulation of cell cycle and
cell division [13,14]. Given its promising bioactivity and
unique structural architecture, many efforts have been de-
voted to chemical syntheses [15-17] and biosynthesis
[18-21] of FDM A. However, the limited yield of FDM A
is still one of the major issues precluding its furtherdevelopment as an anticancer drug. Hence, the rifampi-
cin resistant mutant strain ZH66-RIF1 may serve as an
alternative efficient FDM A producer. To further im-
prove FDM A production rapidly, response surface
methodology (RSM) [22,23] was adopted. Unlike the
conventional one-factor-at-a-time method, RSM is a
mathematical and statistical method used to describe
and predict the response of a multi-variable system
with fewer experiments; therefore, it is much more ef-
ficient in terms of time and cost [24].
Here we report the ribosome engineering of S.
somaliensis SCSIO ZH66 resulting in accumulation of
dark brown pigment, the identification of the compound
with pigment and its encoding gene cluster, and the
rapid enhancement of FDM A production using RSM
methodology.
Results
Ribosome engineering of a deepsea-derived Streptomyces
strain
S. somaliensis SCSIO ZH66 (CGMCC NO.9492) was iso-
lated from the deep-sea sediment collected at a depth of
3536 m of the South China Sea. A 1520-bp 16S rRNA
gene sequence of this strain was determined and com-
pared against the EzTaxon-e server Database [25]. The
result showed that it is highly similar to Streptomyces
16S rRNA with 99% identity to that of Streptomyces
somaliensis (GenBank accession number AB184243).
Therefore, this strain was named as S. somaliensis
SCSIO ZH66. Phylogenetic analysis of strain ZH66 with
its related Streptomyces type strains is shown in
Additional file 1: Figure S1. Considering its unique eco-
logical environment, the genome of strain ZH66 was se-
quenced, which revealed that at least 20 secondary
metabolites biosynthetic gene clusters are existed in this
strain (data not shown). To activate the expression of
cryptic gene clusters, strain ZH66 was subject to ribo-
some engineering. Hence, mutant strain ZH66-RIF1
was generated as described in the Materials and
methods section, which was screened at the presence of
300 μg/mL rifampicin. In contrast to the wild-type
strain ZH66-WT, mutant strain ZH66-RIF1 accumu-
lated dark brown pigment on MS plate (Figure 1A);
HPLC analysis of their ethyl acetate extracts revealed
production of compound 1 by strain ZH66-RIF1 but not
by the wild-type strain (Figure 1C). The mutation in
strain ZH66-RIF1 was then determined to be R444H
in the rpoB gene encoding the β subunit of RNAP
(Figure 1B). In addition, the morphological differenti-
ation of strain ZH66-RIF1 was obviously impaired. As
shown in Additional file 1: Figure S2, the wild-type
strain ZH66-WT sporulated well on Gauze’s No.1
medium when incubated at 30°C for 72 h, while no
sporulation was observed for strain ZH66-RIF1 at the
Figure 1 Comparisons of wild-type strain ZH66-WT and rifampicin-resistant mutant strain ZH66-RIF1. (A) Phenotype of strain ZH66-WT and strain
ZH66-RIF1 on MS plate when incubated at 30°C for 7 days. (B) Comparison of the rpoB genes from strain ZH66-WT and strain ZH66-RIF1. (C) HPLC
traces of strain ZH66-WT and strain ZH66-RIF1. “1” indicates the new compound accumulated by strain ZH66-RIF1.
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for cytotoxicity against three human cancer cell lines.
To our delight, strong inhibitions were observed for
strain ZH66-RIF1 with half-effective concentration (EC50)
of 3.4 mg/mL against A-549, 1.6 mg/mL against HCT116,
and 3.9 mg/mL against P388, indicating compound 1
probably has significant anticancer bioactivity.
Identification of FDM A production from the rifampicin
resistant strain ZH66-RIF1
Given the important role of medium composition for
gene expression [26], strain ZH66-RIF1 was fermented
in different medium to compare the production of com-
pound 1 (Additional file 1: Table S1); among them,
medium-3 gave rise to the best yield of approximate
220.9 mg/L, which was about 30-, 5-, 10- and 13-fold
higher than medium-1 (~7.2 mg/L), 2 (~42.1 mg/L), 4
(~20.9 mg/L) and 5 (~15.6 mg/L), respectively (Additional
file 1: Figure S3). Therefore, fermentation (2 L) was car-
ried out using medium-3, from which compound 1 was
purified and then subject to structural analysis. The UV
spectrum of compound 1 displayed λmax at 260, 302, 316,
332, 357, 373 and 392 nm (Additional file 1: Figure S4),
and the chemical formula of compound 1 was deter-
mined to be C30H21NO9 by HR-ESI-MS (m/z 540.1280
[M + H]+, calcd 540.1295) (Figure 2B). Both are consist-
ent with those of FDM A [12]. The 1H-NMR (Figure 2C)and 13C-NMR (Figure 2D) data of compound 1 were
further recorded, and the chemical shifts were summa-
rized in Additional file 1: Table S2. Taken all the above
data together, the identity of compound 1 was unambigu-
ously confirmed to be the anticancer drug lead FDM A
(Figure 2A). Compared with the previously reported FDM
A producing strains, FDM A titers from Streptomyces
chattanoogensis ISP 5002 [27] and S. griseus ATCC49344
[20] are 10 mg/L and 162 mg/L, respectively. Therefore,
the strain ZH66-RIF1 may serve as an alternative produ-
cer with the FDM A titer reaching 220.9 mg/L when
cultured in medium-3 (Additional file 1: Table S3).
Identification of the FDM A biosynthetic gene cluster
from strain ZH66
In consistent with the production of FDM A, genome
analysis of strain ZH66 revealed the presence of a FDM
gene cluster (herein named frd), which covers about 25-
kb DNA region containing 27 open reading frames (orfs)
with remarkably high homology to their homologs from
S. griseus ATCC49344 (fdm gene cluster) [18] and
Streptomyces sp. SANK61196 (san gene cluster) [28]
(Additional file 1: Table S4). As shown in Figure 3, the
gene composition and organization of these three clus-
ters are highly conserved but with the following excep-
tions: (i) fdmX only exists in the fdm gene cluster, which
putatively encodes a transposase and probably related
Figure 2 Structure determination of FDM A. (A) Chemical structure of FDM A. (B) HRMS data of FDM A. (C) 1H NMR spectrum of FDM A in
DMSO-d6. (D)
13C NMR spectrum of FDM A in DMSO-d6.
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Figure 3 Comparative analyses of the FDM A gene clusters from different Streptomyces strains. (A) fdm, from S. griseus ATCC49344. (B) frd, from
S. somaliensis SCSIO ZH66. (C) san, from Streptomyces sp. SANK61196. The unique gene was marked by a star.
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with unknown function is unique for the san gene clus-
ter; (iii) the counterparts of fdmR2/frdR2 and fdmT3/
frdT3 are absent in the san gene cluster. The sequence
was deposited in the GenBank database under the ac-
cession number KP213175. The production of FDM A
in strain ZH66-RIF1 but not in strain ZH66 suggested
activation of the cryptic frd gene cluster. The transcrip-
tion levels of the frdD gene (encoding polyketide cyclase)
and the frdR1 gene (encoding Streptomyces antibiotic
regulatory protein, SARP) (Additional file 1: Table S4, S5)
were further analyzed by RT-PCR (Figure 4A) and real
time RT-PCR (Figure 4B), confirming that both of them
were substantially transcribed in strain ZH66-RIF1 in
comparison with the wild-type strain ZH66.Figure 4 Transcriptional analysis of frdD and frdR1 genes in wild-type strain
were determined by RT-PCR (A) and real-time RT-PCR (B). The transcription
ZH66-RIF1 grown on MS plates. Error bars indicated standard deviations (nScreening of significant variables for FDM A production
using Plackett-Burman design (PBD)
To further improve FDM A production efficiently, we
screened the significant variables for FDM A production
using PBD. As shown in Additional file 1: Table S6, nine
different factors were tested, including soluble starch
(X1), glucose (X2), corn syrup (X3), yeast extract (X4),
beef extract (X5), CaCO3 (X6), MgSO4 · 7H2O (X7),
KH2PO4 (X8) and sea salt (X9). All the experiments were
performed in triplicate and the average of results (FDM
A titer) were presented as the response in Additional file
1: Table S6. The effect on FDM A production was esti-
mated for each variable (Additional file 1: Table S7). The
Pareto chart (Figure 5) clearly showed that soluble starch
(X1), glucose (X2), and KH2PO4 (X8) had confidenceZH66-WT and rifampicin-resistant mutant strain ZH66-RIF1. Transcripts
levels were detected at 3, 5 and 7 days in strain ZH66-WT and strain
= 3).
Figure 5 The effects of different factors on FDM A production. The bars of the diagram which go beyond the vertical red line correspond to the
statistically significant effects, for a confidence level of 90%.
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ables were selected for further optimization.
Optimization of FDM A production using response
surface methodology
To determine the optimal levels of the above selected
variables, the RSM based on Box-Behnken design (BBD)
was employed. The respective coded levels for each fac-
tor were listed in Additional file 1: Table S8. The experi-
mental design and the corresponding results were
shown in Table 1. By employing multiple regression ana-
lysis on the experimental data, the following equationTable 1 The design of experiments and response of
FDM A production
Run Soluble starch Glucose KH2PO4 FDM A titer
(Y, mg/L)X1 X2 X8
1 −1 −1 0 531.49 ± 5.21
2 −1 1 0 675.39 ± 20.00
3 0 1 −1 684.50 ± 8.08
4 1 −1 0 334.49 ± 19.05
5 0 1 1 548.14 ± 9.34
6 0 0 0 633.26 ± 17.38
7 0 0 0 637.19 ± 8.79
8 1 1 0 484.39 ± 3.57
9 0 −1 −1 513.95 ± 6.54
10 1 0 1 364.40 ± 4.06
11 0 −1 1 398.01 ± 7.40
12 1 0 −1 533.37 ± 3.95
13 0 0 0 628.13 ± 10.49
14 −1 0 1 578.48 ± 8.97
15 −1 0 −1 647.68 ± 8.08was obtained, describing the relationship between FDM
A titer (Y) and the tested variables (X):
Y ¼ 636:19–84:80X1 þ 76:81 X2–66:06X8–65:21X12–64; 543X22
– 35:5X82−29:44X1X8 þ 1:5X1X2−5:105X2X8
Where Y was the predicted FDM A titer; X1, X2 and
X8 were the concentrations of soluble starch, glucose
and KH2PO4, respectively.
To validate the regression coefficient, analysis of vari-
ance (ANOVA) for FDM A production was performed.
The high F-value (62.72) and low p-value (0.000 < 0.05)
implied the model was highly significant (Additional file
1: Table S9). As shown in Table 2, most regression coef-
ficients were highly significant with p-values less than
0.05. The regression analysis of the data showed coeffi-
cient of determination (R2) value of 0.9912 and adjusted
R2 value of 0.9754, which were in close agreement.Table 2 The least-squares fit and coefficient estimate
Variables Coefficient estimate Standard error t-value p-value
Intercept 636.193 10.156 62.644 0.000
X1 −84.799 6.219 −13.635 0.000
X2 76.810 6.219 12.351 0.000
X8 −66.059 6.219 −10.622 0.000
X1
2 −65.210 9.154 −7.124 0.001
X2
2 −64.543 9.154 −7.051 0.001
X8
2 −35.500 9.154 −3.878 0.012
X1X2 1.500 8.795 0.171 0.871
X1X8 −29.442 8.795 −3.348 0.020
X2X8 −5.105 8.795 −0.580 0.587
R2 = 99.12%; R2adj = 97.54%.
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between the observed and predicted responses, indicat-
ing that the model was reliable for FDM A production
in the present study.
The 3D response surfaces and 2D contour plots
(Figure 6) were the graphical representations of the re-
gression equation, which indicated the optimum ranges
of the variables for the maximal response. Clearly, the
FMD A production increased with increase of glucose
concentration (level −1 ~ 0.6), and decrease of solubleFigure 6 3D response surfaces and 2D contour plots for FDM A productio
of FDM A, while the other one variable was held at zero level. (A, B) The e
(C, D) The effects of soluble starch (X1) and KH2PO4 (X8) on FDM A product
production.starch (level 1 ~ −0.75) and KH2PO4 (level 1 ~ −0.7)
concentrations.
Validation of the optimized condition
Based on the above optimized medium composition,
the maximum yield of FDM A was predicted to be
699.84 mg/L when the code levels of X1, X2 and X8
were −0.724 (soluble starch 5.55 g/L), 0.446 (glucose
27.78 g/L), and −0.706 (KH2PO4 0.301 g/L), respectively.
To confirm the predicted results, validation experimentsn. Each figure presented the effect of two variables on the production
ffects of soluble starch (X1) and glucose (X2) on FDM A production.
ion. (E, F) The effects of glucose (X2) and KH2PO4 (X8) on FDM A
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tions, the observed experimental average concentration of
FDM A was 679.5 ± 15.82 mg/L, suggesting that the ex-
perimental and the predicted values (699.84 mg/L) were
in good agreement.
Discussion
Activation of cryptic secondary metabolite biosynthetic
gene clusters and improvement of production of poten-
tial drug leads are two important objects for drug dis-
covery and development [6,7]. Ribosome engineering is
an effective strategy for waking up dormant gene clus-
ters, but the titer of the activated compounds may still
be limited for further chemical and biological evalua-
tions, which would severely hamper their development
as drug candidates. In the present study, a Streptomyces
strain was isolated from the deep sea, and was identified
as S. somaliensis SCSIO ZH66 based on the 16S rDNA
sequence (Additional file 1: Figure S1). A ribosome en-
gineering and RSM integrated strategy was developed to
activate cryptic gene clusters in strain ZH66, and subse-
quently enhance the titer of the activated anticancer
drug lead FDM A (Figure 2), reaching a considerable
yield of 679.5 ± 15.8 mg/L after 7 days of fermentation.
Ribosome engineering is performed using antibiotics
that target either the ribosome itself or RNAP. Drug-
resistant mutants enforced by rifampicin harbor muta-
tions in rpoB gene (encoding the β subunit of RNAP)
[6,7]. Recently, Fu et al. reported the discovery of chlori-
nated alkaloids Inducamides A–C from the rifampicin-
resistant strain Streptomyces sp. SNC-109-M3, which
was identified to contain a S442F mutation in rpoB gene
[10]; while mutant strain ZH66-RIF1 contained a muta-
tion of R444H, which was probably responsible for acti-
vating FDM A production (Figures 1 and 4) and reducing
the growth rate of strain ZH66RIF1 as well (Additional
file 1: Figure S2). Notwithstanding, additional mutations
might also exist in the genome of strain ZH66-RIF1
besides the mutation in RNAP. Notably, activation of
cryptic gene clusters by rpoB mutations was medium-
dependent [9], indicating the important roles of me-
dium composition for the expression of the activated
gene clusters. Hence, strain ZH66-RIF1 was cultured
under different conditions, and the yield of FDM A var-
ied significantly in various medium (Additional file 1:
Figure S3). We assume other compounds with novel
structures might also produce if more culture condi-
tions are screened. In addition, experimental tools such
as HPLC-MS/MS, RT-PCR would probably be necessary
to access the full profile of the activated gene clusters in
strain ZH66-RIF1.
Although strain ZH66 was isolated from the deep sea,
the frd gene cluster exhibited surprisingly high homology
to those from S. griseus ATCC49344 and Streptomycessp. SANK61196 (Figure 3, Additional file 1: Table S1).
The presence of fdmX gene, presumably encoding a
transposase, indicated that the fdm gene cluster in S.
griseus ATCC49344 was probably obtained via horizon-
tal gene transfer (HGT) events from other strains. Since
the homology of frd vs fdm (98-100% identity/similarity
on amino acids level) is much higher than that of frd vs
san (62-94% identity/similarity on amino acids level),
the frd gene cluster should have closer evolution rela-
tionship with the fdm gene cluster than with the san
gene cluster. Intriguingly, in addition to FDM A, the
san gene cluster was reported to encode a structurally
distinct compound A-74528 as well [29]. Nevertheless,
strain ZH66 represented the first FDM A producer iso-
lated from marine environment. Given its promising
value as anticancer drug candidate, enhancement of the
FDM A titer was of interest for its further development.
RSM strategy was adopted to evaluate multiple variables
efficiently, leading to establishment of the optimized
medium composition for FDM A production (Table 1,
Figure 6). Notably, compared with the original medium,
the ratio of soluble starch (slow-acting) to glucose (fast-
acting) was changed from 1:2 (10 g/L to 20 g/L) to ap-
proximately 1:5 (5.55 g/L to 27.78 g/L), suggesting that
low concentration of glucose probably could not meet
the requirement of cell growth thus leading to low yield
of FDM A.
By overexpressing the SARP-type activator gene fdmR1
in S. griseus ATCC49344, the titer of FDM A reached
about 997 mg/L when cultured in APM medium
(medium-2, Additional file 1: Table S1) for 10 days;
since a two-stage fermentation process was adopted, the
total fermentation took 11 to 12 days plus 1 or 2 days
for seed culture; conversely, the titer of FDM A was
about only 400 mg/L on day 7 (not including seed cul-
ture) (Additional file 1: Table S3) [20]. In the present
study, when cultured in APM medium, the FDM A titer
was only one fifth of that in medium-3 (Additional file
1: Figure S3); a titer of 679.5 ± 15.82 mg/L was achieved
in the optimized medium on day 7 in a one-stage fer-
mentation process. In terms of the medium compos-
ition, our optimized medium is much cheaper than
APM medium. Therefore, taking into account of the
medium cost and fermentation time, strain ZH66-RIF1
would be an ideal FDM A producer, which could be ex-
pedient to its pharmaceutical development.
Conclusions
Marine Streptomyces strains serve as important sources
for novel secondary metabolites. However, many second-
ary metabolites biosynthetic gene clusters are “silent” in
typical lab conditions. Ribosome engineering was per-
formed to wake up the cryptic gene clusters in the
deepsea-derived S. somaliensis SCSIO ZH66, leading to
Zhang et al. Microbial Cell Factories  (2015) 14:64 Page 9 of 11activation of a FDM biosynthetic gene cluster, which
showed high homology to the ones from S. griseus
ATCC49344 and Streptomyces sp. SANK61196. RSM
strategy was further adopted to rapidly improve FDM
A accumulation. Among the variables, soluble starch,
glucose and KH2PO4 were found to be the most sig-
nificant. A maximum FDM A production of 679.5 ±
15.82 mg/L was achieved with the optimized medium
developed by RSM, as compared to 220.9 mg/L in
the original medium. Since FDM A was a potential
anticancer drug, the present study provided a new
FDM A producing marine Streptomyces stain and a
more feasible and inexpensive medium for further
large scale fermentation. More importantly, ribosome
engineering and RSM integrated methodology is ef-
fective, fast and efficient for activation of cryptic gene
cluster and the subsequent titer optimization, which
would facilitate novel compounds discovery and their suffi-
cient production for further pharmaceutical development.
Material and methods
Microorganism and culture conditions
S. somaliensis SCSIO ZH66 (CGMCC NO.9492) was iso-
lated from the deep sea sediment collected at a depth of
3536 meters of the South China Sea (120° 0.250′E; 20°
22.971′N). The strain was grown at 30°C on MS
medium for sporulation. Five fermentation media as de-
scribed in the supplemental materials (Additional file 1:
Table S1) were screened to detect the FDM A produc-
tion, among which medium-2 was chosen as the start
medium for further optimization. For each fermentation,
strain ZH66RIF-1 spores were inoculated into 50 mL of
fermentation medium supplemented with 2% XAD-16
resin in a 250 mL flask, and incubated at 30°C, 240 rpm
for 7 days.
Identification of the actinomycete strain
Genomic DNA was prepared according to the literature
protocol [29]. The 1520-bp 16S rRNA gene was ampli-
fied by PCR using the primer pair of 16S-FP/16S-RP
(Additional file 1: Table S4). The 16S rRNA gene se-
quence was compared against the EzTaxon-e server
Database [25] to retrieve the most similar sequences of
type strains. Phylogenetic analysis of the 16S rRNA gene
sequences were performed using the Molecular Evolu-
tionary Genetics Analysis (MEGA) software [30], and
the substitution model was Poisson correction. Primer
synthesis and DNA sequencing were performed at
Sunny Biotech Co. Ltd. (Shanghai, China).
Ribosome engineering of strain ZH66
Firstly, the minimum inhibitory concentrations (MIC) of
rifampicin against strain ZH66 were determined. Spore
suspensions (106 spores) were spread onto MS platescontaining different concentrations (0–50 μg/mL) of ri-
fampicin. The plates were incubated at 30°C for 5 days.
The minimum concentration that fully inhibited the
growth of strain ZH66 was defined as the MIC value,
which turned out to be 10 μg/mL. Spore suspensions
(109 spores) were then spread onto MS plates containing
rifampicin at concentrations of 30 to 300 μg/mL. Mutant
colonies producing the darkest pigment were selected,
generating mutant strain ZH66-RIF1 which was ob-
tained on the MS plate containing 300 μg/mL rifampi-
cin. To map the mutation in the genome of strain
ZH66RIF-1, the rpoB gene was amplified using Q5 high-
fidelity DNA polymerase (New England Biolabs, Beverly,
MA, USA) with the primer pair of rpoB-FP/rpoB-RP
(Additional file 1: Table S4). The amplified DNA frag-
ment was digested with BamHI and HindIII, and then
was ligated into the same sites of pUC18 to yield
pUC18::rpoB-RIF1. After confirmation by enzymatic di-
gestion, three clones were subject to sequencing to
analyze the mutation in rpoB gene.
Genomic scanning and sequence analysis
Genomic DNA was shotgun sequenced using commer-
cial 454 technology by Shanghai Majorbio Bio-pharm
Technology Co., Ltd. (Shanghai, China). orf assignments
and their proposed function were accomplished by using
the FramePlot 4.0beta (http://nocardia.nih.go.jp/fp4) [31]
and Blast programs (http://blast.ncbi.nlm.nih.gov/Blast.
cgi) [32], respectively.
Biological assays
Cytotoxicity assays were performed at the Molecular
Screening Facility at School of Pharmacy, Ocean
University of China (Qingdao, China), by using the
SRB method (against A-549 and HCT116), or the
MTT method (against P388).
Production and analyses of FDM A
The fermentation cultures were harvested by centrifuga-
tion, and the supernatant was extracted twice with an
equal volume of ethyl acetate. The combined EtOAc ex-
tracts were concentrated in vacuo to afford residue A.
The precipitated mycelia and XAD-16 resin were ex-
tracted twice with acetone. The extracts were combined,
and acetone was evaporated in vacuo to yield residue B.
The combined residues were dissolved in 95:5 mixture
of CHCl2-MeOH, filtered through a 0.2 μm filter, and
subject to HPLC. The HPLC system consisted of Agilent
1260 Infinity Quaternary pumps and a 1260 Infinity
diode-array detector. Analytical HPLC was performed
on an Eclipse C18 column (5 μm, 4.6 × 150 mm) devel-
oped with a linear gradient from 65% to 100% B/A
(phase A: 0.1% formic acid in H2O; phase B: 100% aceto-
nitrile supplemented with 0.1% formic acid) in 20 min
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of 1 mL/min and UV detection at 260 nm. For FDM A
purification, semi-preparative HPLC was carried out
using an YMC-Pack ODS-A C18 column (5 μm, 120 nm,
250 × 10 mm). Samples were eluted with a linear gradient
from 50% to 95% B/A in 40 min, followed by 100% B for
10 min at a flow rate of 2.0 mL/min and UV detection at
260 nm. The identity of FDM A was confirmed by HRMS
and NMR analysis. HRMS was carried out on Thermo
LTQ-XL mass spectrometer. NMR data was recorded with
a Bruker Avance 600 spectrometer.
Transcriptional analysis by RT-PCR and real-time RT-PCR
Total RNAs were prepared using Ultrapure RNA Kit
(CWBio. Inc., Beijing, China). The genomic DNA was
removed with gDNA Eraser (Takara Bio, Inc., Dalian,
China). Synthesis of the first strand cDNA was per-
formed with PrimeScript RT reagent Kit (Takara Bio,
Inc., Dalian, China). The reaction parameters of reverse
transcription PCR (RT-PCR) were as follows: 95°C for
5 min, followed by 30 cycles consisting of 95°C for 30 s,
60°C for 30 s, 72°C for 45 s and a final extension of 72°C
for 10 min. Quantitative real-time reverse transcription
PCR (real-time RT-PCR) was performed on an ABI7500
real-time PCR system (Applied Biosystems) in triplicate
for each sample using the SYBR green method. Each re-
action mixture contained 5 μL of SYBR Premix Ex Taq
(Takara Bio, Inc., Dalian, China), 0.2 μL of ROX Refer-
ence Dye II (50×), 0.5 μL of 2.5-fold diluted cDNA,
0.2 μL of each primer at a concentration of 0.2 pmol μL−1
(Additional file 1: Table S4) and 3.4 μL ddH2O. The PCR
procedures were as follows: 95°C for 10 min, 40 cycles
95°C for 15 s and 60°C for 1 min. The hrdB gene
(Additional file 1: Table S4) was used as the reference
for RT-PCR and real-time RT-PCR.
Identifying the significant variables using
Plackett-Burman design
Preliminary investigation of factors affecting the FDM A
production was done by using PBD [33]. The variables
chosen for the present study were investigated at two
widely spaced intervals designated as −1 (low level) and +1
(high level). The experimental design for screening the
medium components was shown in Additional file 1:
Table S6. The effects of individual parameters on FDM








Where, E is the effect of parameter under study and M+
and M− are responses (FDM A titer) of trials at which the
parameter was at its higher and lower levels, respectively,
and N is the total number of trials.Optimization by Box-Behnken design
Levels of the significant parameters and the interaction
effects between various media constituents, which sig-
nificantly influence FDM A production, were analyzed
and optimized by BBD [34,35]. In this study, the experi-
mental plan consisted of 15 trials and the independent
variables were studied at three different levels (−1, 0, 1).
All the experiments were done in triplicate and the aver-
age of FDM A production obtained was taken as the re-
sponse (Y). The second order polynomial coefficients
were calculated and analyzed using Minitab16. The gen-
eral form of the second degree polynomial equation is:









Where, Y is the predicted response, XiXj are input vari-
ables which influence the response variable Y; β0 is the
offset term; βi is the ith linear coefficient; βii is the ith
quadratic coefficient and βij is the ijth interaction coeffi-
cient. Statistical analysis of the model was performed in
the form of ANOVA. This analysis included the Fisher’s
F-test (overall model significance), its associated prob-
ability P(F), correlation coefficient R, and determination
coefficient R2 which measures the goodness of fit of re-
gression model. For each variable, the quadratic models
were represented as counter plots and response surface
curves which were generated using Minitab16.
Software for experimental design
The software Minitab16 was used for generation and
evaluation of the statistical experimental design. The op-
timal medium composition for FDM A production was
obtained by solving the regression equation and by ana-
lyzing the response surface contour plots using the same
software.
Nucleotide sequence accession number
The nucleotide sequences of the 16S rRNA gene, the
rpoB gene and the frd gene cluster reported in this paper
have been deposited in the GenBank database under ac-
cession numbers of KB146142, KP722021 and KP213175,
respectively.
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